- Home
- GECC vs KLRS Comparison
GECC vs KLRS Comparison
Compare GECC & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- KLRS
- Stock Information
- Founded
- GECC 2016
- KLRS 2019
- Country
- GECC United States
- KLRS United States
- Employees
- GECC N/A
- KLRS N/A
- Industry
- GECC Finance: Consumer Services
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GECC Finance
- KLRS Health Care
- Exchange
- GECC Nasdaq
- KLRS Nasdaq
- Market Cap
- GECC 116.9M
- KLRS 129.0M
- IPO Year
- GECC N/A
- KLRS N/A
- Fundamental
- Price
- GECC $10.85
- KLRS $3.48
- Analyst Decision
- GECC
- KLRS Buy
- Analyst Count
- GECC 0
- KLRS 1
- Target Price
- GECC N/A
- KLRS N/A
- AVG Volume (30 Days)
- GECC 23.9K
- KLRS 62.3K
- Earning Date
- GECC 05-05-2025
- KLRS 05-19-2025
- Dividend Yield
- GECC 13.55%
- KLRS N/A
- EPS Growth
- GECC N/A
- KLRS N/A
- EPS
- GECC 0.42
- KLRS N/A
- Revenue
- GECC $42,909,000.00
- KLRS N/A
- Revenue This Year
- GECC $14.33
- KLRS N/A
- Revenue Next Year
- GECC N/A
- KLRS N/A
- P/E Ratio
- GECC $25.73
- KLRS N/A
- Revenue Growth
- GECC 18.13
- KLRS N/A
- 52 Week Low
- GECC $8.87
- KLRS $4.19
- 52 Week High
- GECC $11.39
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- GECC 67.15
- KLRS N/A
- Support Level
- GECC $10.47
- KLRS N/A
- Resistance Level
- GECC $10.25
- KLRS N/A
- Average True Range (ATR)
- GECC 0.27
- KLRS 0.00
- MACD
- GECC 0.11
- KLRS 0.00
- Stochastic Oscillator
- GECC 91.31
- KLRS 0.00
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.